Idorsia Shares Retreat Despite Positive Trial Data for Sleep Drug

Market Reaction Contrasts with Strong Clinical Findings

Shares of the biopharmaceutical firm Idorsia declined by 2.50% yesterday to close at CHF 4.09. This pullback occurred even as the company presented new, favorable clinical trial data for its insomnia treatment, QUVIVIQ. The drop represents a classic “sell the news” event, with investors securing profits following a significant rally of over 9% the previous day.

At the “World Sleep 2025” congress, Idorsia unveiled fresh clinical analyses for daridorexant, marketed as QUVIVIQ. The latest data reinforces the drug’s profile, highlighting a lower potential for abuse compared to other insomnia therapies. This characteristic is viewed as a critical competitive edge for gaining further market share.